← Insulin × glycemic control

TrialDiabetes, obesity & metabolism2019

Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT02607306. Its numbers are set against the trial’s posted results below.

  • IDegLiracuts both waysLower long-term blood sugar, lower severe or blood glucose-confirmed hypoglycaemia, higher severe or blood glucose-confirmed hypoglycaemia.Randomised, small.

What the trial testedrandomised · 819 people · 2019

Randomised vs degludec

Probably lowered long-term blood sugar

−6.91mmol/mol−8.18 to −5.64

IDegLira vs degludec

As reported

difference −6.91 mmol/mol, 95% CI −8.18 to −5.64 · the paper's word: glycated haemoglobin (HbA1c)

Randomised vs degludec

Probably lowered severe or blood glucose-confirmed hypoglycaemia

−52%−65% to −32%

IDegLira vs degludec

Bigger than 5 in 10 for glycemic control

As reported

IRR 0.48, 95% CI 0.35–0.68 · the paper's word: Rates of severe or blood glucose-confirmed hypoglycaemia

Randomised vs liraglutide

Probably raised severe or blood glucose-confirmed hypoglycaemia

38×20× to 71×

IDegLira vs liraglutide

Bigger than almost all for glycemic control

As reported

IRR 37.58, 95% CI 19.8–71.3 · the paper's word: Rates of severe or blood glucose-confirmed hypoglycaemia

Randomised vs liraglutide

Probably lowered long-term blood sugar

Doesn’t vote: same as the registry's posted result, which counts instead

−5.30mmol/mol−6.58 to −4.03

IDegLira vs liraglutide

As reported

difference −5.30 mmol/mol, 95% CI −6.58 to −4.03 · the paper's word: glycated haemoglobin (HbA1c)

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −5.30 (−6.58 to −4.03)Posted, primary outcome difference −0.48 (−0.60 to −0.37), p <0.0001Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira
  • Same as the trial’s posted resultThis paper difference −6.91 (−8.18 to −5.64)Posted, primary outcome difference −0.63 (−0.75 to −0.52), p <0.0001Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira

Who was studied, and how

819people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

IDegLira
degludec

Probably lowered long-term blood sugar−6.91

Probably lowered severe or blood glucose-confirmed hypoglycaemia−52%

randomised

The trial randomly assignedassigned by chance

IDegLira
liraglutide

Probably lowered long-term blood sugar−5.30

Probably raised severe or blood glucose-confirmed hypoglycaemia38×

randomised

the abstract, start to end

… estimated treatment differences were -6.91 mmol/mol (95% confidence interval [CI] -8.18; -5.64) and -5.30 mmol/mol (95% CI -6.58; -4.03), …

… were lower versus degludec (rate ratio 0.48 [95% CI 0.35; 0.68]; P < .0001), but higher versus liraglutide (rate ratio 37.58 [95% CI 19.80; 71.31]; …

← favours treatmentfavours comparator →
could be chance
Glycated haemoglobin (HbA1c)IDegLira vs degludec
−6.91−8.18 to −5.64
Glycated haemoglobin (HbA1c)IDegLira vs liraglutide
−5.30−6.58 to −4.03
Rates of severe or blood glucose-confirmed hypoglycaemiaIDegLira vs degludec
IRR 0.480.35–0.68
Rates of severe or blood glucose-confirmed hypoglycaemiaIDegLira vs liraglutide
IRR 37.5819.8–71.3
InsulinGlycemic controlAdverse events & safety
1 / 5

18 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT02607306phase 3819 enrolled2015this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 31407845